Rethinking Brain Health with Transformational Innovation

We use rigorous science to develop our industry-leading, evidence-based pipeline of product candidates that have the potential to transform the treatment landscape for brain health disorders.

We strive to deliver on the therapeutic potential of psychedelics and other novel compounds to address unmet patient needs in:

Generalized Anxiety Disorder (GAD)1
20M
adults in the U.S. live with GAD
Major Depressive Disorder (MDD)1
31M
adults in the U.S. live with MDD
Autism Spectrum Disorder (ASD)2
5.4M
adults in the U.S. live with ASD

The therapies we are investigating are not approved by the FDA or any other countries’ Health Authorities. This means their safety and efficacy are still being evaluated and have not been established.

  1. Ringeisen, H., Edlund, M. J., Guyer, H., Geiger, P., Stambaugh, L. F., Dever, J. A., Liao, D., Carr, C. M., Peytchev, A., Reed, W., McDaniel, K., & Smith, T. K. (2023). Mental and Substance Use Disorders Prevalence Study: Findings report. RTI International.
  2. Dietz PM, Rose CE, McArthur D, Maenner M. National and State Estimates of Adults with Autism Spectrum Disorder. J Autism Dev Disord. 2020;50(12):4258-4266.

Learn More About Our Mission and Areas of Focus

Research & Development Pipeline

Our pipeline offers opportunities across diverse therapeutic areas and mechanisms of action

Explore MindMed’s R&D Programs to learn more about the opportunities that exist to advance novel treatments for a wide range of brain health disorders.